Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Aptar Pharma discusses Physiologically based PK models for OINDPs.
Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs
Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Download the Q&A This article presents an insightful conversation with Dr Irene Rossi on the subject of Nasal Drug Product Development. It delves into the current trends and technical challenges associated with nasal drug formulation. The discussion emphasizes the growing recognition of ‘Nose-to-Brain’ delivery as a promising method to tackle disorders of the brain and […]
Nanopharm cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
